Bionet (ROCO:1784) Other Stockholders Equity: NT$43 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1784 Bionet Corp ROCO:1784
77 GF Score
Price NT$58.70
GF Value NT$82.34
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Bionet Other Stockholders Equity?

Bionet ROCO:1784 +1.03% 77 Other Stockholders Equity is NT$43 Mil as of Mar. 2026. GuruFocus rates ROCO:1784 with a GF Score™ of 77/100 and a GF Value™ of NT$82.34 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Bionet's Other Stockholders Equity for the quarter that ended in Mar. 2026 was NT$43 Mil.

Bionet's quarterly Other Stockholders Equity declined from Sep. 2025 (NT$42 Mil) to Dec. 2025 (NT$42 Mil) but then increased from Dec. 2025 (NT$42 Mil) to Mar. 2026 (NT$43 Mil).

Bionet's annual Other Stockholders Equity increased from Dec. 2023 (NT$27 Mil) to Dec. 2024 (NT$33 Mil) and increased from Dec. 2024 (NT$33 Mil) to Dec. 2025 (NT$42 Mil).

Bionet Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bionet's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Other Stockholders Equity Chart

Bionet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.34 23.26 26.81 33.07 42.17

Bionet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.41 41.95 42.37 42.17 42.58
ROCO:1784
77GF Score
Bionet Corp ROCO:1784
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionet Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$43 Mil mean?
Bionet (ROCO:1784) has a Other Stockholders Equity of NT$43 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bionet and its competitors.
Is Bionet's Other Stockholders Equity too high?
Bionet's current Other Stockholders Equity is NT$43 Mil. Overall, Bionet has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionet's Other Stockholders Equity compare to TMO and DHR?
Bionet's Other Stockholders Equity of NT$43 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bionet and its competitors. Bionet's current Other Stockholders Equity is NT$43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet stock overvalued right now?
Based on GuruFocus' analysis, Bionet (ROCO:1784) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$82.34, compared to a current price of NT$58.70 — trading 28.7% below its estimated fair value. The current Other Stockholders Equity is NT$43 Mil. Bionet's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bionet (ROCO:1784), the current Other Stockholders Equity is NT$43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionet (ROCO:1784) Overvalued in 2026?

Based on GuruFocus' analysis, Bionet stock appears to be undervalued. The current stock price of NT$58.70 is trading 28.7% below its estimated GF Value™ of NT$82.34. GuruFocus considers Bionet to be Modestly Undervalued.

Key valuation signals for ROCO:1784:

  • Other Stockholders Equity: NT$43 Mil
  • GF Value™: NT$82.34 vs. price of NT$58.70 (28.7% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the ROCO:1784 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionet Business Description

Address No.28, Lane 36, Xinhu 1st Road, Neihu District, Taipei, TWN, 114065
Bionet Corp provides blood bank and stem cell services. It is a preservation center for stem cells such as Umbilical Cord Mesenchymal Stem Cells and Dental Pulp Stem Cell Stem.
77GF Score

Get the complete analysis for ROCO:1784

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.70
Price
NT$82.34
GF Value